Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386283669> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W4386283669 endingPage "4060" @default.
- W4386283669 startingPage "4055" @default.
- W4386283669 abstract "Background/Aim: This study retrospectively investigated the impact of enfortumab vedotin (EV) monotherapy on the oncological outcome, safety profile, and health-related quality of life (HRQoL) in patients with metastatic urothelial carcinoma. Patients and Methods: We assessed 26 consecutive patients who had received EV monotherapy after failure of platinum-based chemotherapy and immune checkpoint blockade therapy at our single institution from December 2021 to January 2023. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), incidence of adverse events (AEs), and EORTC QLQ-C30 as an HRQoL instrument were evaluated. Results: The ORR and DCR were 57.7% and 80.8%, respectively. EV was effective regardless of the patient and tumor characteristics, including the efficacy of previous systemic therapy, performance status, number of Bellmunt risk factors, and presence of variant histology. With a median follow-up time of 7.5 months, the median durations of PFS and OS were 5.4 months and 10.3 months, respectively. Grade ≥3 AEs included neutropenia (15.4%), fatigue (7.7%), appetite loss (7.7%), rash (3.8%), febrile neutropenia (3.8%), hyperglycemia (3.8%), and interstitial pneumonia (3.8%). AEs resulting in withdrawal of EV, interruption of EV, and dose reduction occurred in two (7.7%), nine (34.6%), and 13 patients (50.0%), respectively. The EORTC QLQ-C30 scores from baseline to post-EV introduction remained stable. Conclusion: EV monotherapy demonstrated promising anti-tumor activity and tolerability in patients with metastatic urothelial carcinoma." @default.
- W4386283669 created "2023-08-31" @default.
- W4386283669 creator A5009716651 @default.
- W4386283669 creator A5010953950 @default.
- W4386283669 creator A5020076297 @default.
- W4386283669 creator A5040776712 @default.
- W4386283669 creator A5047054113 @default.
- W4386283669 creator A5064983825 @default.
- W4386283669 creator A5068689907 @default.
- W4386283669 creator A5075825992 @default.
- W4386283669 creator A5076462635 @default.
- W4386283669 creator A5081326354 @default.
- W4386283669 creator A5082566636 @default.
- W4386283669 creator A5083259432 @default.
- W4386283669 creator A5084462870 @default.
- W4386283669 creator A5091118998 @default.
- W4386283669 creator A5061025648 @default.
- W4386283669 date "2023-08-30" @default.
- W4386283669 modified "2023-10-14" @default.
- W4386283669 title "Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World" @default.
- W4386283669 doi "https://doi.org/10.21873/anticanres.16594" @default.
- W4386283669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37648337" @default.
- W4386283669 hasPublicationYear "2023" @default.
- W4386283669 type Work @default.
- W4386283669 citedByCount "1" @default.
- W4386283669 crossrefType "journal-article" @default.
- W4386283669 hasAuthorship W4386283669A5009716651 @default.
- W4386283669 hasAuthorship W4386283669A5010953950 @default.
- W4386283669 hasAuthorship W4386283669A5020076297 @default.
- W4386283669 hasAuthorship W4386283669A5040776712 @default.
- W4386283669 hasAuthorship W4386283669A5047054113 @default.
- W4386283669 hasAuthorship W4386283669A5061025648 @default.
- W4386283669 hasAuthorship W4386283669A5064983825 @default.
- W4386283669 hasAuthorship W4386283669A5068689907 @default.
- W4386283669 hasAuthorship W4386283669A5075825992 @default.
- W4386283669 hasAuthorship W4386283669A5076462635 @default.
- W4386283669 hasAuthorship W4386283669A5081326354 @default.
- W4386283669 hasAuthorship W4386283669A5082566636 @default.
- W4386283669 hasAuthorship W4386283669A5083259432 @default.
- W4386283669 hasAuthorship W4386283669A5084462870 @default.
- W4386283669 hasAuthorship W4386283669A5091118998 @default.
- W4386283669 hasBestOaLocation W43862836691 @default.
- W4386283669 hasConcept C121608353 @default.
- W4386283669 hasConcept C126322002 @default.
- W4386283669 hasConcept C143998085 @default.
- W4386283669 hasConcept C197934379 @default.
- W4386283669 hasConcept C2776694085 @default.
- W4386283669 hasConcept C2776907518 @default.
- W4386283669 hasConcept C2777063308 @default.
- W4386283669 hasConcept C2778375690 @default.
- W4386283669 hasConcept C2778570526 @default.
- W4386283669 hasConcept C2778850193 @default.
- W4386283669 hasConcept C2780352672 @default.
- W4386283669 hasConcept C2911057145 @default.
- W4386283669 hasConcept C3019882237 @default.
- W4386283669 hasConcept C71924100 @default.
- W4386283669 hasConcept C90924648 @default.
- W4386283669 hasConceptScore W4386283669C121608353 @default.
- W4386283669 hasConceptScore W4386283669C126322002 @default.
- W4386283669 hasConceptScore W4386283669C143998085 @default.
- W4386283669 hasConceptScore W4386283669C197934379 @default.
- W4386283669 hasConceptScore W4386283669C2776694085 @default.
- W4386283669 hasConceptScore W4386283669C2776907518 @default.
- W4386283669 hasConceptScore W4386283669C2777063308 @default.
- W4386283669 hasConceptScore W4386283669C2778375690 @default.
- W4386283669 hasConceptScore W4386283669C2778570526 @default.
- W4386283669 hasConceptScore W4386283669C2778850193 @default.
- W4386283669 hasConceptScore W4386283669C2780352672 @default.
- W4386283669 hasConceptScore W4386283669C2911057145 @default.
- W4386283669 hasConceptScore W4386283669C3019882237 @default.
- W4386283669 hasConceptScore W4386283669C71924100 @default.
- W4386283669 hasConceptScore W4386283669C90924648 @default.
- W4386283669 hasIssue "9" @default.
- W4386283669 hasLocation W43862836691 @default.
- W4386283669 hasLocation W43862836692 @default.
- W4386283669 hasOpenAccess W4386283669 @default.
- W4386283669 hasPrimaryLocation W43862836691 @default.
- W4386283669 hasRelatedWork W1196768483 @default.
- W4386283669 hasRelatedWork W2062191467 @default.
- W4386283669 hasRelatedWork W2072029106 @default.
- W4386283669 hasRelatedWork W2102925359 @default.
- W4386283669 hasRelatedWork W2128269008 @default.
- W4386283669 hasRelatedWork W2138054646 @default.
- W4386283669 hasRelatedWork W2160583837 @default.
- W4386283669 hasRelatedWork W2371615325 @default.
- W4386283669 hasRelatedWork W4286110999 @default.
- W4386283669 hasRelatedWork W4312753031 @default.
- W4386283669 hasVolume "43" @default.
- W4386283669 isParatext "false" @default.
- W4386283669 isRetracted "false" @default.
- W4386283669 workType "article" @default.